drugset
drugset / Trial / NCT02800928

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

NCT02800928 ↗

Phase 2 Completed 17 enrolled Yale University Janssen Pharmaceuticals · collabNational Institute on Drug Abuse (NIDA) · collabOffice of Research on Women's Health (ORWH) · collab
RandomizedCrossoverDouble-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Stress-precipitated Smoking Behavior.

Timeline

Start
2016-06-30
Primary completion
2018-01-02
Completion
2018-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aticaprant Small molecule 10 mg Oral

Indications

No indication recorded.